Ralph Weichselbaum to Radiotherapy
This is a "connection" page, showing publications Ralph Weichselbaum has written about Radiotherapy.
Connection Strength
8.327
-
Radiotherapy induces YTHDF2 in dendritic cells impairing cross-presentation and T cell function. J Exp Med. 2026 01 05; 223(1).
Score: 0.792
-
The dark side of radiotherapy. Cancer Cell. 2025 Aug 11; 43(8):1385-1389.
Score: 0.774
-
YTHDFs as radiotherapy checkpoints in tumor immunity. J Exp Med. 2025 Aug 04; 222(8).
Score: 0.770
-
Radiotherapy and immunology. J Exp Med. 2024 07 01; 221(7).
Score: 0.716
-
Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):17-26.
Score: 0.553
-
Radiotherapy and Immunotherapy for Cancer: From "Systemic" to "Multisite". Clin Cancer Res. 2020 06 15; 26(12):2777-2782.
Score: 0.533
-
Tumor-reprogrammed resident T cells resist radiation to control tumors. Nat Commun. 2019 09 02; 10(1):3959.
Score: 0.516
-
Integration of radiotherapy and immunotherapy for treatment of oligometastases. Lancet Oncol. 2019 08; 20(8):e434-e442.
Score: 0.513
-
Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. Oncotarget. 2016 Jul 12; 7(28):43039-43051.
Score: 0.415
-
The role of radiotherapy in locally advanced pancreatic carcinoma. Nat Rev Gastroenterol Hepatol. 2010 Aug; 7(8):437-47.
Score: 0.274
-
Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers. Cancer Gene Ther. 2009 Aug; 16(8):609-19.
Score: 0.253
-
Radiation's outer limits. Nat Med. 2005 May; 11(5):477-8.
Score: 0.191
-
Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation. Lancet Oncol. 2025 Mar; 26(3):e152-e170.
Score: 0.189
-
Relevance and irrelevance of DNA damage response to radiotherapy. DNA Repair (Amst). 2004 Aug-Sep; 3(8-9):1245-51.
Score: 0.181
-
Radioimmunoscintigraphy for postprostatectomy radiotherapy: analysis of toxicity and biochemical control. J Nucl Med. 2004 Aug; 45(8):1315-22.
Score: 0.181
-
Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol. 2002 Nov; 3(11):665-71.
Score: 0.161
-
Molecular targeting of gene therapy and radiotherapy. Acta Oncol. 2001; 40(6):735-8.
Score: 0.142
-
Non-canonical NF-?B Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy. Immunity. 2018 09 18; 49(3):490-503.e4.
Score: 0.120
-
Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. Nat Commun. 2018 06 15; 9(1):2351.
Score: 0.119
-
Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. PLoS One. 2018; 13(4):e0195149.
Score: 0.117
-
Radiogenetic therapy: on the interaction of viral therapy and ionizing radiation for improving local control of tumors. Semin Oncol. 1997 Dec; 24(6):633-8.
Score: 0.114
-
Radiation oncology. JAMA. 1996 Jun 19; 275(23):1852-3.
Score: 0.103
-
Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs. Clin Exp Metastasis. 2014 Aug; 31(6):735-48.
Score: 0.090
-
Radiation oncology. JAMA. 1994 Jun 01; 271(21):1712-4.
Score: 0.090
-
gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr Cancer Drug Targets. 2006 May; 6(3):197-205.
Score: 0.051
-
Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference. Oncoimmunology. 2025 Dec; 14(1):2432726.
Score: 0.047
-
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol. 2000 Apr; 18(8):1652-61.
Score: 0.034
-
Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):450-461.
Score: 0.027
-
Conservative surgery and adjuvant radiation therapy in the management of adult soft tissue sarcoma of the extremities: clinical and radiobiological results. Int J Radiat Oncol Biol Phys. 1995 Jul 15; 32(4):977-85.
Score: 0.024
-
Racial parities in outcomes after radiotherapy for head and neck cancer. Cancer. 2014 Jan 15; 120(2):244-52.
Score: 0.021
-
Possible applications of biotechnology to radiotherapy. Eur J Cancer. 1991; 27(4):405-7.
Score: 0.018
-
Palliative radiotherapy. Hematol Oncol Clin North Am. 1990 Dec; 4(6):1169-81.
Score: 0.018
-
Monosomy 12p in a radiation-induced germ cell tumor. Genes Chromosomes Cancer. 1990 Sep; 2(3):186-90.
Score: 0.017
-
Outcomes in black patients with early breast cancer treated with breast conservation therapy. Int J Radiat Oncol Biol Phys. 2011 Feb 01; 79(2):392-9.
Score: 0.017
-
Breast conserving surgery and definitive irradiation for early stage breast cancer. Int J Radiat Oncol Biol Phys. 1989 Dec; 17(6):1211-6.
Score: 0.016
-
Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009 Jul 16; 114(3):589-95.
Score: 0.016
-
Extended mantle radiation therapy for pathologic stage I and II Hodgkin's disease. J Clin Oncol. 1988 Jun; 6(6):1047-52.
Score: 0.015
-
Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008 Apr 01; 26(10):1732-41.
Score: 0.015
-
Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. Int J Oncol. 2006 May; 28(5):1141-51.
Score: 0.013
-
Forphenicinol enhances the antitumor effects of cyclophosphamide in a model of squamous cell carcinoma. Cancer Chemother Pharmacol. 2005 Sep; 56(3):317-21.
Score: 0.012
-
Glioblastoma cells block radiation-induced programmed cell death of endothelial cells. FEBS Lett. 2004 May 07; 565(1-3):167-70.
Score: 0.011
-
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol. 2004 Feb 15; 22(4):592-601.
Score: 0.011
-
Combined gene therapy and ionizing radiation is a novel approach to treat human esophageal adenocarcinoma. Ann Surg Oncol. 2002 Jun; 9(5):500-4.
Score: 0.010
-
Toxicity of aggressive multimodality therapy including cisplatinum, bleomycin and methotrexate with radiation and/or surgery for advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 1982 May; 8(5):909-13.
Score: 0.010
-
Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease. Ann Oncol. 1996 Nov; 7(9):913-8.
Score: 0.007
-
Perspectives on combination chemotherapy with concomitant radiotherapy for poor-prognosis head and neck cancer. Semin Oncol. 1992 Aug; 19(4 Suppl 11):47-56.
Score: 0.005
-
Treatment complications after sequential combination chemotherapy and radiotherapy with or without surgery in previously untreated squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1985 Nov; 11(11):1887-93.
Score: 0.003
-
Incidence of hypothyroidism following multimodality treatment for advanced squamous cell cancer of the head and neck. Laryngoscope. 1984 Apr; 94(4):451-54.
Score: 0.003